GLUCOTROL XL (glipizide) by Pfizer is pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. First approved in 1994.
Drug data last refreshed 14h ago
GLUCOTROL XL (glipizide) is an extended-release oral sulfonylurea approved in 1994 for Type 2 Diabetes Mellitus and hyperglycemia. It works by binding to sulfonylurea receptors on pancreatic beta cells, closing ATP-sensitive potassium channels and stimulating insulin release. The drug is indicated for Type 2 Diabetes, hyperglycemia, chronic kidney disease, and atherosclerosis management.
Product is in late-stage lifecycle with minimal Part D spending ($91K, 1,442 claims in 2023), indicating significant erosion and shrinking team investment.
pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
Sulfonylurea
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)
Worked on GLUCOTROL XL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWith zero linked jobs and a product in LOE-Approaching stage, GLUCOTROL XL offers minimal career growth or visibility. Roles available are primarily defensive—managing generic conversion, retaining legacy accounts, and supporting field teams in markets where the brand still holds residual share among price-sensitive or therapy-stable patients.